• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 25, 2022
Discovery & Translation

AACR22 tackles the CAR T solid tumor challenge

Dual-targeting CARs, new targets and bispecific adaptors among the top innovations
Read More
BioCentury | Feb 10, 2022
Discovery & Translation

Translational trendspotting: a Distillery dive into neurology

Highlights include a new approach to the amyloid hypothesis, white space strategies for stroke and gene therapies
Read More
BioCentury | Apr 7, 2021
Distillery Therapeutics

RECK, an inhibitor of amyloid precursor protein cleavage, as a target for Alzheimer’s

DISEASE CATEGORY: Neurology
INDICATION: Alzheimer’s disease Blocking RECK, a membrane-tethered inhibitor of APP-cleaving enzyme ADAM10, could treat Alzheimer’s disease. Levels of
Read More
BioCentury | Jul 18, 2020
Translation in Brief

Fate licenses rejection-resistant T cell therapies; plus a marker for anti-PD-1 treatment responsiveness, a cell proliferation control switch and more

BioCentury’s roundup of preclinical news
Read More
BioCentury | Dec 8, 2017
Translation in Brief

ADAM and Ephrin

Researchers target ADAM10 in lung fibrosis
Read More
BioCentury | Oct 24, 2017
Distillery Therapeutics

Pulmonary

Read More
BioCentury | Sep 26, 2017
Distillery Therapeutics

Cancer

Read More
BioCentury | Sep 20, 2017
Preclinical News

Inhibiting ADAM10 could help treat brain cancer

Read More
BioCentury | Jul 13, 2017
Targets & Mechanisms

Insider signaling

Takeda believes endosomal signaling for substance P could revive the pain target
Read More
BioCentury | Sep 29, 2016
Distillery Techniques

Techniques: Panel of 12 hippocampal proteins to diagnose early stage Alzheimer's disease

Read More
Items per page:
1 - 10 of 13